Who is sponsoring NCT03108352?

NCT03108352 is sponsored by Chengdu Kanghong Biotech Co., Ltd..

What drugs are being tested in NCT03108352?

Interventions in NCT03108352: Conbercept ophthalmic injection, sham/Conbercept ophthalmic injection.

What condition does NCT03108352 study?

NCT03108352 studies Branch Retinal Vein Occlusion, Macular Edema.

Is NCT03108352 still recruiting?

NCT03108352 is currently completed. Last updated 15 July 2022.

Last reviewed 2022-07-15 · How we verify

NCT03108352: BRAVE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion

Completed Phase 3 Last updated 15 July 2022

What this trial tests

Phase 3 trial testing Conbercept ophthalmic injection in Branch Retinal Vein Occlusion in 255 participants. Completed in 16 October 2020.

Timeline

13 April 2016

Primary endpoint
13 April 2020

16 October 2020

Quick facts

Lead sponsor	Chengdu Kanghong Biotech Co., Ltd.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	255
Start date	13 April 2016
Primary completion	13 April 2020
Estimated completion	16 October 2020
Sites	31 locations across China

Drugs / interventions tested

Conbercept ophthalmic injection — full drug profile →
sham/Conbercept ophthalmic injection

Conditions studied

Branch Retinal Vein Occlusion — all drugs for Branch Retinal Vein Occlusion →
Macular Edema — all drugs for Macular Edema →

Sponsor

Chengdu Kanghong Biotech Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Branch Retinal Vein Occlusion or Macular Edema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to verify the efficacy and safety of intravitreal injection of conbercept in patients with macular edema (ME) caused by branch retinal vein occlusion (BRVO).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Retinal and choroidal angiogenesis: a review of new targets.
Cabral T, Mello LGM, Lima LH, Polido J, et al · · 2017 · cited 114× · PMID 28835854 · DOI 10.1186/s40942-017-0084-9
An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma.
Ghanchi F, Bourne R, Downes SM, Gale R, et al · · 2022 · cited 35× · PMID 34974541 · DOI 10.1038/s41433-021-01766-w
Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Shalchi Z, Mahroo O, Bunce C, Mitry D. · · 2020 · cited 26× · PMID 32633861 · DOI 10.1002/14651858.cd009510.pub3
Ocular Delivery of Therapeutic Agents by Cell-Penetrating Peptides.
Nhàn NTT, Maidana DE, Yamada KH. · · 2023 · cited 25× · PMID 37048144 · DOI 10.3390/cells12071071

Verify or expand the search:

Other trials of Conbercept ophthalmic injection

Trials testing the same drug.

NCT04990271 — A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Inject · Phase 2 · unknown

Other recruiting trials for Branch Retinal Vein Occlusion

Currently open trials in the same condition.

NCT05476926 — A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products · active not recruiting

Other Chengdu Kanghong Biotech Co., Ltd. trials

Trials by the same sponsor.

NCT06885645 — First-In-Human Study in Participants With Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT04990271 — A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Inject · Phase 2 · unknown
NCT04555304 — Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Ther · Phase 2 · unknown
NCT03630952 — Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) · Phase 3 · terminated
NCT03577899 — Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03108352 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chengdu Kanghong Biotech Co., Ltd.
Last refreshed: 15 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03108352.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing